KI II

Karolinska Institutet II, Stockholm, Sweden

Group Description

Brief description of legal entity
The Karolinska Institutet (KI), as leading European medical university, conducts more than forty per cent of all academic medical research in Sweden. A total of 1,500 researchers, 2,000 doctoral students and 1,000 laboratory technicians participate in the activities. The Department of Geriatric Medicine, Karolinska University Hospital Huddinge provides services for cognitive disorders in a catchment area of approximately 1,000,000 inhabitants in Stockholm with a special responsibility for patients with memory disturbances below 65 years of age. Approximately 2,000 patients are visiting the department per year and of these approximately more than 700 patients are new patients undergoing assessment for memory problem per year with an assessment battery that including neuropsychology testing, structural imaging and CSF sampling. The KI has a strong focus on patients with mild cognitive impairment (MCI), on longitudinal studies of subjects at risk of familial Alzheimer´s disease (AD; mutation carriers) and on clinical trials of new drugs in AD.

Main tasks
PET studies in multi-tracer concept with [11C]PIB (amyloid), [11C]deprenyl (astrocytes), [18F]FDG (glucose metabolism), 18F-THK5317 (tau) in subject at risk of familial AD, MCI and AD patients. MicroPET studies with [11C]PiB and [11C]deprenyl in APPswe transgenic mice prior and after treatment with compounds targeting APP/Aß and inflammatory cascade. Immunohistochemical, biochemical and proteomics of CSF for biomarker screening.

Participation in INMiND:  WP2 / WP5 / WP6 / WP8 .

Previous experience relevant to INMiND tasks

Multi-tracer PET studies in AD and MCI patients ([11C]PIB, [11C]nicotine, [11C]PMP, [18F]FDG, [11C]deprenyl) for detection of early changes in AD and understanding of time course of pathological changes as well as outcome of treatment with different cholinesterase inhibitors, nerve-growth factors (FP5 NEST-DD; FP6 DiMI). Multi-centre clinical imaging trials involving AD and MCI patients within DiMI (www.dimi.eu) were [11C]PIB-PET imaging was observed as an excellent marker for early AD detection (Nordberg et al. 2013).


Karolinska Institute
Prof Agneta NORDBERG
INMiND Office
European Institute for Molecular Imaging (EIMI) Waldeyerstr. 15
· 48149 Münster
Tel: +49 251 83 49300 · Fax: +49 251 83 49313
E-Mail: